CH Biotech R&D Balance Sheet Health
Financial Health criteria checks 6/6
CH Biotech R&D has a total shareholder equity of NT$2.6B and total debt of NT$563.4M, which brings its debt-to-equity ratio to 21.5%. Its total assets and total liabilities are NT$3.6B and NT$951.2M respectively. CH Biotech R&D's EBIT is NT$477.6M making its interest coverage ratio -150.2. It has cash and short-term investments of NT$598.4M.
Key information
21.5%
Debt to equity ratio
NT$563.36m
Debt
| Interest coverage ratio | -150.2x |
| Cash | NT$598.36m |
| Equity | NT$2.62b |
| Total liabilities | NT$951.24m |
| Total assets | NT$3.57b |
Recent financial health updates
CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt
Apr 05
Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?
Dec 15
Recent updates
CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt
Apr 05A Look At CH Biotech R&D's (GTSM:6534) Share Price Returns
Mar 18Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Feb 09Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting Picture
Jan 11Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?
Dec 15Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend Yield
Nov 24Financial Position Analysis
Short Term Liabilities: 6534's short term assets (NT$814.3M) exceed its short term liabilities (NT$586.9M).
Long Term Liabilities: 6534's short term assets (NT$814.3M) exceed its long term liabilities (NT$364.3M).
Debt to Equity History and Analysis
Debt Level: 6534 has more cash than its total debt.
Reducing Debt: 6534's debt to equity ratio has reduced from 67.4% to 21.5% over the past 5 years.
Debt Coverage: 6534's debt is well covered by operating cash flow (87.6%).
Interest Coverage: 6534 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 05:06 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CH Biotech R&D Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Hsiu Chi Lin | Masterlink Securities Corp. |